Travere Therapeutics Announces 2024 Annual Meeting of Stockholders on May 8, 2024

TL;DR

<b>Travere Therapeutics will hold its 2024 Annual Meeting of Stockholders on May 8, 2024.</b>

AI Summary

Travere Therapeutics, Inc. (TVTX) filed a Proxy Statement (DEF 14A) with the SEC on March 27, 2024. Travere Therapeutics, Inc. will hold its 2024 Annual Meeting of Stockholders on May 8, 2024. The meeting will commence at 9:00 a.m. Pacific Time. The filing is a Definitive Proxy Statement (DEF 14A). The company's fiscal year ends on December 31. The company was formerly known as Retrophin, Inc. and Desert Gateway, Inc.

Why It Matters

For investors and stakeholders tracking Travere Therapeutics, Inc., this filing contains several important signals. This DEF 14A filing provides essential information for stockholders regarding the upcoming annual meeting, including details on voting matters and executive compensation. The meeting date is critical for shareholders to participate in corporate governance decisions, such as electing directors and approving executive compensation plans.

Risk Assessment

Risk Level: low — Travere Therapeutics, Inc. shows low risk based on this filing. The filing is a routine proxy statement and does not contain new financial or operational disclosures that would significantly alter the company's risk profile.

Analyst Insight

Stockholders should review the proxy statement to understand the proposals being voted on and make informed decisions regarding their proxy votes.

Key Numbers

• 2024-05-08 — Annual Meeting Date (Date of Annual Meeting of Stockholders)
• 9:00 — Annual Meeting Time (Time of Annual Meeting of Stockholders)
• 2023-12-31 — Fiscal Year End (Company's Fiscal Year End)
• 20240327 — Filing Date (Date the DEF 14A was filed)

Key Players & Entities

• Travere Therapeutics, Inc. (company) — Registrant
• May 8, 2024 (date) — Date of Annual Meeting
• 9:00 a.m. (time) — Time of Annual Meeting
• San Diego, CA (location) — Company Address
• Retrophin, Inc. (company) — Former Company Name
• Desert Gateway, Inc. (company) — Former Company Name

FAQ

Industry Context

Travere Therapeutics is a biopharmaceutical company focused on developing therapies for rare diseases. This filing is typical for publicly traded companies preparing for their annual shareholder meetings.

Regulatory Implications

This filing is made under Schedule 14A of the Securities Exchange Act of 1934, which governs the solicitation of proxies from shareholders.

What Investors Should Do

1. Review the full proxy statement for details on director nominees and voting proposals.
2. Consider the company's past performance and future outlook when making voting decisions.
3. Ensure your proxy is submitted by the deadline to be counted for the Annual Meeting.

Key Dates

• 2024-05-08: Annual Meeting of Stockholders — Key date for shareholder participation in corporate decisions.
• 2024-03-27: Filing Date — Date the Definitive Proxy Statement was filed with the SEC.

Year-Over-Year Comparison

This is the initial filing for the 2024 Annual Meeting of Stockholders, following the typical DEF 14A format.

Key Financial Figures

• $10,500 — ill pay Alliance Advisors approximately $10,500 plus out-of-pocket expenses, for its as

Filing Documents

• tvtx-20240327.htm (DEF 14A) — 1397KB
• tvtx-20240327_g1.jpg (GRAPHIC) — 38KB
• tvtx-20240327_g2.jpg (GRAPHIC) — 30KB
• tvtx-20240327_g3.jpg (GRAPHIC) — 30KB
• tvtx-20240327_g4.jpg (GRAPHIC) — 8KB
• tvtx-20240327_g5.jpg (GRAPHIC) — 10KB
• tvtx-20240327_g6.jpg (GRAPHIC) — 10KB
• tvtx-20240327_g7.jpg (GRAPHIC) — 11KB
• 0001438533-24-000012.txt (&nbsp;) — 2424KB
• tvtx-20240327.xsd (EX-101.SCH) — 4KB
• tvtx-20240327_def.xml (EX-101.DEF) — 5KB
• tvtx-20240327_lab.xml (EX-101.LAB) — 7KB
• tvtx-20240327_pre.xml (EX-101.PRE) — 5KB
• tvtx-20240327_htm.xml (XML) — 129KB

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS These proxy materials contain "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on our current expectations and involve risks and uncertainties. Forward-looking statements may include statements regarding clinical development programs and trials, potential regulatory filings and regulatory decisions and the timing thereof, expected benefits of and future activities under collaboration agreements, future milestones future commercial performance, statements regarding the expected or potential benefits of the proposed amendment to the 2018 Equity Incentive Plan as described in Proposal 2, and other forward-looking information in Proposal 2. No forward-looking statement can be guaranteed and actual results may differ materially from those stated or implied by forward-looking statements. We undertake no obligation to publicly update any forward-looking statement, except as required under applicable law. Forward-looking statements should be evaluated together with the many risks and uncertainties that affect our business, particularly those mentioned under the "Risk Factors" heading of our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on February 20, 2024. 5

SECURITY OWNERSHIP OF

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT The following table sets forth certain information regarding the ownership of the Company's common stock as of March 1, 2024 by: (i) each director and director nominee, (ii) each named executive officer, (iii) each person known by us to beneficially own more than 5% of all outstanding shares of our common stock, and (iv) all executive officers and directors of the Company as a group. The table is based upon information supplied by our executive officers and directors and a review of Schedules 13D and 13G filed with the SEC. Unless otherwise indicated in the footnotes to the table and subject to community property laws where applicable, we believe that each of the stockholders named in the table has sole voting and investment power with respect to the shares indicated as beneficially owned. Applicable percentages are based on 76,098,485 shares outstanding on March 1, 2024, adjusted as required by rules promulgated by the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities. In addition, the rules include shares of common stock issuable pursuant to the exercise of stock options, warrants or other convertible securities that are either immediately exercisable or exercisable on or before April 30, 2024, which is 60 days after March 1, 2024, or issuable pursuant to restricted stock units that vest on or before April 30, 2024. These shares are deemed to be outstanding and beneficially owned by the person holding those securities for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise stated below, the address for each person or entity listed in the table is c/o Travere Therapeutics, Inc., 3611 Valley Centre Drive, Suite 300, San Diego, Califor

View Full Filing

View this DEF 14A filing on SEC EDGAR